A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants With Chronic Kidney Disease and High Proteinuria

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin/zibotentan (Primary) ; Dapagliflozin
Indications Renal failure
Focus Registrational; Therapeutic Use
Acronyms ZENITH High Proteinuria
Sponsors AstraZeneca

Most Recent Events

14 Jan 2025 Planned End Date changed from 5 Jan 2027 to 22 Jan 2027.
14 Jan 2025 Planned primary completion date changed from 5 Jan 2027 to 22 Jan 2027.
28 Nov 2024 Planned End Date changed from 30 Jun 2027 to 5 Jan 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight